NCT00784719

A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.

A Phase I/II Prospective, Randomized, Double Masked, Vehicle And Comparator Controlled, Dose Ranging Study Of CP-690,550 In Subjects With Dry Eye Disease.

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 327 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A prospective, randomized, placebo and active comparator controlled study of CP-690,550 in subjects with dry eye.

Conditions

• Dry Eye Syndromes

Interventions

Type	Name	Description
DRUG	CP-690,550	Ophthalmic topical solution, low dose, dosed at least once/day, 8 weeks
DRUG	CP-690,550	Ophthalmic topical solution, medium dose, dosed at least once/day, 8 weeks
DRUG	CP-690,550	Ophthalmic topical solution, intermediate dose, dosed at least once/day, 8 weeks
DRUG	CP-690,550	Ophthalmic topical solution, high dose, dosed at least once/day, 8 weeks
DRUG	Cyclosporine	Ophthalmic topical solution, 0.05%, dosed at least once/day, 8 weeks
DRUG	CP-690,550 Vehicle	Ophthalmic topical solution, dosed at least once/day, 8 weeks

Timeline

• Start date: 2008-11-01
• Primary completion: 2009-10-01
• Completion: 2009-10-01
• First posted: 2008-11-04
• Last updated: 2013-04-09
• Results posted: 2013-04-09

Locations

27 sites across 1 country: United States